Attovia Therapeutics IPO
Attovia Therapeutics, Inc. · Biopharmaceuticals (immune-mediated diseases)
- Issue price
- $17per share
- Issue size
- $289M1,70,00,000 shares
- Face value
- To be announcedper equity share
- Lot size
- To be announcedMin. investment shown once set
- PricingTue, 2026
Information only, not investment advice. This page provides information compiled from official SEC filings for information purposes only. It is not investment advice or a recommendation to buy or sell any security. IPO investments involve risk, including loss of principal; read the prospectus carefully before investing.
Issue details
- Issue type
- Firm commitment, fresh issue
- Fresh issue
- 1,70,00,000 shares ($268.77M)
- Offer for sale
- None
- Total issue
- 1,70,00,000 shares ($289M)
- Face value
- —
- Listing at
- Nasdaq
Source: Final prospectus (Form 424B4) dated 5 Aug 2026Updated
Valuation
Year ended December 31, 2024- EPS (basic)
- -$12.76
- EPS (diluted)
- -$12.76
- EPS (basic) (Year ended December 31, 2025)
- -$15.42
- EPS (diluted) (Year ended December 31, 2025)
- -$15.42
- EPS (basic) (Three months ended March 31, 2025)
- -$4.05
- EPS (diluted) (Three months ended March 31, 2025)
- -$4.05
- EPS (basic) (Three months ended March 31, 2026)
- -$4.49
- EPS (diluted) (Three months ended March 31, 2026)
- -$4.49
Source: Final prospectus (Form 424B4) dated 5 Aug 2026Updated
Financials
Consolidated, restated · ₹ crore| Period ended | 31 Mar 20263 months | 31 Dec 202512 months | 31 Mar 20253 months | 31 Dec 202412 months |
|---|---|---|---|---|
| Revenue from operations | 0.00 | 0.14 | 0.00 | 0.00 |
| Profit after tax | -1.87 | -6.06 | -1.52 | -3.98 |
| Net worth | -12.55 | — | — | — |
| Total assets | 14.61 | — | — | — |
12 months vs 12 months: profit after tax −52.3%. Periods shorter than 12 months are shown as reported and are not annualised.
Source: Final prospectus (Form 424B4) dated 5 Aug 2026Updated
About the company
Attovia is a clinical-stage biopharmaceutical company developing biologic therapies for immune-mediated diseases. Its candidates are built on its ATTOBODY platform, which uses biparatopic VHH-based building blocks that can be combined into multispecific and conditional 'AND' gate biologics. Its lead candidate, ATTO-1310, is in a Phase 1 trial targeting IL-31 for chronic itch conditions.
- Incorporated
- —
- Industry
- Biopharmaceuticals (immune-mediated diseases)
- Sector
- Healthcare and Pharma
- Website
- attovia.com
Source: Final prospectus (Form 424B4) dated 5 Aug 2026Updated
Promoters and shareholders
| Name | Before issue | After issue |
|---|---|---|
| Frazier Life Sciences XI, L.P. | 21.30% | 12.90% |
| venBio Global Strategic Fund IV, L.P. | 14.60% | 8.80% |
| Alamar HoldCo, LLC | 12.40% | 7.50% |
| Entities affiliated with Goldman Sachs & Co. LLC | 9.30% | 5.70% |
| Deep Track Biotechnology Master Fund, Ltd | 7.50% | 4.50% |
Source: Final prospectus (Form 424B4) dated 5 Aug 2026Updated
Objects of the issue
| Purpose | Amount |
|---|---|
| Advance ATTO-1310 through Phase 2 studies in chronic pruritus of unknown origin and high-itch atopic dermatitis (range of $110.0 million to $130.0 million) | Set with price |
| Advance ATTO-2306 through a Phase 2 study in moderate-to-severe atopic dermatitis (range of $60.0 million to $80.0 million) | Set with price |
| Fund the rest of the research pipeline, including ATTO-1091 Phase 1 work, other R&D, working capital and general corporate purposes | Set with price |
Source: Final prospectus (Form 424B4) dated 5 Aug 2026Updated
Strengths and risks
Our summary of what the offer document statesSource: Final prospectus (Form 424B4) dated 5 Aug 2026Updated
Contacts
Source: Final prospectus (Form 424B4) dated 5 Aug 2026Updated
After listing
Listing price, day-one high and low, and the change from the issue price ($17) appear here after the shares list on Nasdaq.
Work out the gain or loss on allotted shares after charges →
Frequently asked questions
What is the Attovia Therapeutics IPO price band?
The final issue price is $17 per share.
Where will Attovia Therapeutics shares list?
On Nasdaq.
Related IPOs
More healthcare and pharma IPOs
- Latigo Biotherapeutics$18Listed
- BlossomHill Therapeutics$16Listed
- Braveheart Bio$18Listed
- Vogenx$13Listed
Also managed by Morgan Stanley & Co. LLC
All Morgan Stanley & Co. LLC IPOs →Spotted something wrong?
Our data comes from official offer documents, but mistakes can slip through. Report an error and tell us which figure looks wrong and where you saw the correct one (the offer-document page number helps). For anything else, see Contact.